Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew J Weickhardt

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Molecular Oncology|May 26, 2017
K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell linesYvonne Yeung, David K Lau, Fiona Chionh, et al.
Asia-Pacific Journal of Clinical Oncology|January 11, 2018
Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancerAnis A Hamid, Kaspar Willson, Andrew D Vincent, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2012
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancerAndrew J Weickhardt, Benjamin Scheier, Joseph Malachy Burke, et al.
Molecular Cancer Research : MCR|December 4, 2013
ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular driversDara L Aisner, Teresa T Nguyen, Diego D Paskulin, et al.
Cancer|January 28, 2012
Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancerRobert C Doebele, Xian Lu, Christopher Sumey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2012
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancerAndrew J Weickhardt, Tim J Price, Geoff Chong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2012
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancerRobert C Doebele, Amanda B Pilling, Dara L Aisner, et al.
Cancer|April 16, 2013
Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patientsAndrew J Weickhardt, Robert C Doebele, W Thomas Purcell, et al.
Molecular Cancer Therapeutics|February 10, 2021
Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEKDavid K Lau, Ian Y Luk, Laura J Jenkins, et al.
Scientific Reports|January 25, 2022
VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancerFiona Chionh, Val Gebski, Sheren J Al-Obaidi, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Molecular Oncology|May 26, 2017
K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell linesYvonne Yeung, David K Lau, Fiona Chionh, et al.
Asia-Pacific Journal of Clinical Oncology|January 11, 2018
Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancerAnis A Hamid, Kaspar Willson, Andrew D Vincent, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2012
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancerAndrew J Weickhardt, Benjamin Scheier, Joseph Malachy Burke, et al.
Molecular Cancer Research : MCR|December 4, 2013
ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular driversDara L Aisner, Teresa T Nguyen, Diego D Paskulin, et al.
Cancer|January 28, 2012
Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancerRobert C Doebele, Xian Lu, Christopher Sumey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2012
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancerAndrew J Weickhardt, Tim J Price, Geoff Chong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2012
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancerRobert C Doebele, Amanda B Pilling, Dara L Aisner, et al.
Cancer|April 16, 2013
Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patientsAndrew J Weickhardt, Robert C Doebele, W Thomas Purcell, et al.
Molecular Cancer Therapeutics|February 10, 2021
Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEKDavid K Lau, Ian Y Luk, Laura J Jenkins, et al.
Scientific Reports|January 25, 2022
VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancerFiona Chionh, Val Gebski, Sheren J Al-Obaidi, et al.
Pageof 3